Probiotics-based Anticancer Immunity In Lung Cancer

Pp: 236-261 (26)

* (Excluding Mailing and Handling)

Abstract

Among various death-causing diseases, the morbidity and mortality related to cancer are the highest, with millions of new malignancies added to the tally every year and predicted to increase at a higher rate by 2030. Lung cancer is continued to be the leading cause of cancer death worldwide, with a share of 11.6% of all cancers. Since the start of the millennium, there has been a continuous effort to provide the benefits of probiotics in the management and treatment of cancer, particularly lung cancer. Probiotics are defined as “live microorganisms which, when administered in adequate amounts, confer health benefits on the host”. These include specific strains of bacteria and fungi. Bacterial strains belonging to Lactobacillus and Bifidobacterium have demonstrated promising results in the prevention, attenuation, and treatment of the progression of lung cancer. The present chapter focuses on the types and aetiology of lung cancer and the role and mechanism of action of probiotics in providing immunity against lung cancer.

Cite as